ERBB2 and breast carcinoma: A study by Müller et al. suggests that the benefit of T-DM1 in HER2-positive breast cancer might partly be due to immune system activation, as shown by an increase in tumor-infiltrating lymphocytes (TILs) following neoadjuvant treatment [6].